2016
Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey
Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey. Cancer 2016, 123: 449-458. PMID: 27690182, PMCID: PMC5297986, DOI: 10.1002/cncr.30325.Peer-Reviewed Original ResearchConceptsPatient respondentsPhysician respondentsTreatment goalsPhysicians' self-reported practicesProportion of patientsImportant treatment goalSatisfaction of patientsPatient-physician communicationPrognostic risk classificationSelf-reported practicesThrombotic eventsCommon symptomsSymptom improvementPatient recollectionSymptom assessmentPatients' perceptionsPatient educationDelay progressionImportant symptomPatientsRisk classificationSymptomsDisease managementLandmark surveyOne-thirdMyeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey
Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer 2016, 16: 167. PMID: 26922064, PMCID: PMC4769833, DOI: 10.1186/s12885-016-2208-2.Peer-Reviewed Original ResearchConceptsPrognostic risk scoreMyeloproliferative neoplasmsRisk scorePolycythemia veraEssential thrombocythemiaDisease burdenDaily livingOverall healthSymptom severityMedian disease durationLandmark surveyPatient's overall healthOverall disease burdenRisk of mortalityMedian respondent ageLower symptom severityDisease durationSymptom burdenPatients' qualityMPN subtypesTreatment managementPatientsConclusionsThese findingsResultsThe surveyQoL
2014
Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY
Mesa R, Miller C, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Dubinski D, Boyle J, Mascarenhas J. Gaps in Perception Between Patients and Physicians Regarding Symptomatology and Treatment Attitudes for Myeloproliferative Neoplasms: MPN LANDMARK SURVEY. Blood 2014, 124: 4827. DOI: 10.1182/blood.v124.21.4827.4827.Peer-Reviewed Original ResearchPatient-physician communicationIncyte CorporationPrognostic risk scoreImportant treatment goalMost patientsDisease burdenMajority of physiciansTreatment goalsMyeloproliferative neoplasmsPolycythemia veraEssential thrombocythemiaPrognostic riskPhysicians' perceptionsSpeakers bureauRisk scoreDisease settingsPoor patient-physician communicationFourth of patientsPrimary treatment recommendationLandmark surveyThird of patientsOverall managementDisease-related symptomsAdvisory CommitteeYears of ageImpact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States
Mesa R, Miller C, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Dubinski D, Boyle J, Mascarenhas J. Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Overall Health and Productivity: Results from the MPN LANDMARK SURVEY in the United States. Blood 2014, 124: 3183. DOI: 10.1182/blood.v124.21.3183.3183.Peer-Reviewed Original ResearchPrognostic risk scoreMajority of patientsIncyte CorporationLow-risk scoresRisk scoreMyeloproliferative neoplasmsEssential thrombocythemiaOverall healthSymptom burdenDays of workSpeakers bureauPolycythemia veraSignificant burdenSubset of patientsTotal symptom scoreImpact of symptomsAdvisory CommitteeHigh-risk scoreChronic myeloproliferative neoplasmsNovartis Pharmaceuticals CorporationQuality of lifeLandmark surveyMarked burdenEligible patientsSymptom scores